[go: up one dir, main page]

SK11022001A3 - Vetvené aminokyselinové dependentné aminotransferázové inhibítory a ich použitie pri liečení diabetickej retinopatie - Google Patents

Vetvené aminokyselinové dependentné aminotransferázové inhibítory a ich použitie pri liečení diabetickej retinopatie Download PDF

Info

Publication number
SK11022001A3
SK11022001A3 SK1102-2001A SK11022001A SK11022001A3 SK 11022001 A3 SK11022001 A3 SK 11022001A3 SK 11022001 A SK11022001 A SK 11022001A SK 11022001 A3 SK11022001 A3 SK 11022001A3
Authority
SK
Slovakia
Prior art keywords
acetic acid
cyclohexyl
methyl
hydrochloride salt
dimethyl
Prior art date
Application number
SK1102-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Justin Stephen Bryans
Lain-Yen Hu
Susan M. Hutson
Kathryn Foley Lanoue
Erich Leith
Michael Francis Rafferty
Todd Robert Ryder
Ti-Zhi Su
Devin Franklin Welty
David Juergen Wustrow
Original Assignee
Warner-Lambert Company
The Penn State Research Foundation
Wake Forest University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, The Penn State Research Foundation, Wake Forest University filed Critical Warner-Lambert Company
Publication of SK11022001A3 publication Critical patent/SK11022001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1102-2001A 1999-12-08 2000-11-08 Vetvené aminokyselinové dependentné aminotransferázové inhibítory a ich použitie pri liečení diabetickej retinopatie SK11022001A3 (sk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16963599P 1999-12-08 1999-12-08
US17539900P 2000-01-11 2000-01-11
US23002000P 2000-09-05 2000-09-05
PCT/US2000/030769 WO2001042191A1 (en) 1999-12-08 2000-11-08 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy

Publications (1)

Publication Number Publication Date
SK11022001A3 true SK11022001A3 (sk) 2002-11-06

Family

ID=27389690

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1102-2001A SK11022001A3 (sk) 1999-12-08 2000-11-08 Vetvené aminokyselinové dependentné aminotransferázové inhibítory a ich použitie pri liečení diabetickej retinopatie

Country Status (33)

Country Link
EP (1) EP1157000B1 (is)
JP (1) JP2003516379A (is)
KR (1) KR20010101811A (is)
CN (2) CN1170811C (is)
AP (1) AP2001002242A0 (is)
AR (1) AR037738A1 (is)
AT (1) ATE308510T1 (is)
AU (1) AU784553B2 (is)
BG (1) BG105875A (is)
BR (1) BR0008443A (is)
CA (1) CA2361647A1 (is)
CO (1) CO5280055A1 (is)
CZ (1) CZ20012758A3 (is)
DE (1) DE60023657T2 (is)
DZ (1) DZ3141A1 (is)
EA (1) EA006597B1 (is)
EE (1) EE200100416A (is)
ES (1) ES2252075T3 (is)
GE (1) GEP20043298B (is)
HK (1) HK1044933B (is)
HR (1) HRP20010581A2 (is)
HU (1) HUP0200570A3 (is)
IS (1) IS6033A (is)
MA (1) MA26777A1 (is)
MX (1) MXPA01008085A (is)
NO (1) NO20013844L (is)
OA (1) OA11759A (is)
PE (1) PE20010929A1 (is)
PL (1) PL349193A1 (is)
SK (1) SK11022001A3 (is)
UY (1) UY26474A1 (is)
WO (1) WO2001042191A1 (is)
YU (1) YU57401A (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ATE540678T1 (de) 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA02010231A (es) 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MXPA02010430A (es) * 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
DE602004010135T2 (de) * 2004-09-20 2008-09-04 Kao Corp. Verfahren zur Herstellung von Lactonen und deren Verwendung als Geruchsstoffe
RU2440112C2 (ru) 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008155619A2 (en) * 2007-06-21 2008-12-24 Pfizer Inc. Preparation of optically-active cyclic amino acids
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2481801A1 (en) * 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
EP2717869B1 (en) * 2011-06-13 2019-02-27 Ergon Pharmaceuticals LLC Methods of treatment using a bcat1 inhibitor
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
CN111635937B (zh) * 2020-06-29 2021-10-08 江苏省中医院 Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE9800309A (et) * 1996-03-14 1999-02-15 Warner-Lambert Company Uued asendatud tsüklilised aminohapped kui farmatseutilised toimeained

Also Published As

Publication number Publication date
HUP0200570A3 (en) 2003-02-28
HUP0200570A2 (en) 2002-06-29
ATE308510T1 (de) 2005-11-15
IS6033A (is) 2001-07-31
MXPA01008085A (es) 2002-04-24
DE60023657T2 (de) 2006-07-20
DZ3141A1 (fr) 2001-01-14
AP2001002242A0 (en) 2001-09-30
EE200100416A (et) 2002-12-16
NO20013844D0 (no) 2001-08-07
EA200100791A1 (ru) 2002-04-25
NO20013844L (no) 2001-10-04
CA2361647A1 (en) 2001-06-14
HK1044933B (zh) 2005-06-03
CN1626069A (zh) 2005-06-15
MA26777A1 (fr) 2004-12-20
AU784553B2 (en) 2006-05-04
YU57401A (sh) 2004-05-12
AU1477901A (en) 2001-06-18
GEP20043298B (en) 2004-03-10
CN1170811C (zh) 2004-10-13
EP1157000A1 (en) 2001-11-28
PL349193A1 (en) 2002-07-01
AR037738A1 (es) 2004-12-01
EA006597B1 (ru) 2006-02-24
JP2003516379A (ja) 2003-05-13
UY26474A1 (es) 2001-01-31
CN1344245A (zh) 2002-04-10
ES2252075T3 (es) 2006-05-16
HK1044933A1 (en) 2002-11-08
HRP20010581A2 (en) 2002-08-31
BR0008443A (pt) 2001-10-30
WO2001042191A1 (en) 2001-06-14
BG105875A (en) 2002-05-31
PE20010929A1 (es) 2001-09-08
OA11759A (en) 2005-07-19
CZ20012758A3 (cs) 2002-09-11
CO5280055A1 (es) 2003-05-30
KR20010101811A (ko) 2001-11-14
EP1157000B1 (en) 2005-11-02
DE60023657D1 (de) 2005-12-08

Similar Documents

Publication Publication Date Title
RS57401B1 (sr) Terapeutski aktivna jedinjenja i postupci za njihovu upotrebu
SK11022001A3 (sk) Vetvené aminokyselinové dependentné aminotransferázové inhibítory a ich použitie pri liečení diabetickej retinopatie
US7329746B2 (en) Macrocyclic beta-secretase inhibitors for the treatment of Alzheimer's disease
AU2003208538B2 (en) Amino acids with affinity for the alpha-2-delta-protein
KR102349776B1 (ko) 눈 질환의 치료를 위한 조성물 및 방법
MXPA04004105A (es) Metodo de tratamiento de tinnitus.
US20030119826A1 (en) Neuroprotective treatment methods using selective iNOS inhibitors
IL316611A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
AU2004275572A1 (en) Therapeutic beta aminoacids
ZA200106260B (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy.
US6632831B2 (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
UA75572C2 (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
US20030109522A1 (en) Ophthalmologic treatment methods using selective iNOS inhibitors
WO2026008076A1 (zh) 含一氧化氮供体的黄酮类衍生物
WO2026008075A1 (zh) 含一氧化氮供体的化合物
JP2002535272A (ja) 抗炎症剤
JP2025511181A (ja) アザスピロノナンコアを含むｔ型カルシウムチャネル調節因子及びその使用方法